Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
15.50
+0.29 (1.91%)
At close: Feb 27, 2026, 4:00 PM EST
15.77
+0.27 (1.74%)
After-hours: Feb 27, 2026, 7:47 PM EST
Cullinan Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
111
Market Cap
915.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 18.94M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 211.09M |
| Maravai LifeSciences Holdings | 185.74M |
| ARS Pharmaceuticals | 142.77M |
| Xencor | 125.58M |
| CytomX Therapeutics | 113.63M |
| Theravance Biopharma | 80.33M |
| uniQure | 15.75M |
| Arbutus Biopharma | 14.61M |
CGEM News
- 5 days ago - Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 days ago - Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist - Seeking Alpha
- 10 days ago - Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript - Seeking Alpha
- 11 days ago - Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit - GlobeNewsWire
- 24 days ago - Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 4 weeks ago - Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers - Seeking Alpha
- 7 weeks ago - Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript - Seeking Alpha